Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada.
A(H3N2)
Influenza
clade
observational study
test-negative design
vaccine effectiveness
Journal
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
28
9
2022
Statut:
ppublish
Résumé
Influenza virus circulation virtually ceased in Canada during the COVID-19 pandemic, re-emerging with the relaxation of restrictions in spring 2022. Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network reports 2021/22 vaccine effectiveness of 36% (95% CI: -38 to 71) against late-season illness due to influenza A(H3N2) clade 3C.2a1b.2a.2 viruses, considered antigenically distinct from the 3C.2a1b.2a.1 vaccine strain. Findings reinforce the World Health Organization's decision to update the 2022/23 northern hemisphere vaccine to a more representative A(H3N2) clade 3C.2a1b.2a.2 strain.
Identifiants
pubmed: 36148674
doi: 10.2807/1560-7917.ES.2022.27.38.2200720
pmc: PMC9511683
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Euro Surveill. 2019 Nov;24(46):
pubmed: 31771709
Lancet Reg Health Am. 2021 Sep;1:100015
pubmed: 34386788
Stat Med. 2002 Aug 30;21(16):2409-19
pubmed: 12210625
Euro Surveill. 2019 Nov;24(48):
pubmed: 31796152
Clin Infect Dis. 2022 Aug 24;75(1):e564-e571
pubmed: 35325923
J Postgrad Med. 2016 Jan-Mar;62(1):26-31
pubmed: 26732193
Cell Rep. 2022 May 31;39(9):110897
pubmed: 35649381
J Infect Dis. 2020 Jan 1;221(1):8-15
pubmed: 31665373
Euro Surveill. 2019 Nov;24(48):
pubmed: 31796156